{"disease":{"id":"diffuse-large-b-cell-lymphoma-dlbcl","name":"diffuse large b cell lymphoma dlbcl"},"drugs":{"marketed":[{"drug_id":"allr3","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"loncastuximab","indication_name":"diffuse large B-cell lymphoma (DLBCL) not otherwise specified","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zynlonta","generic_name":"LONCASTUXIMAB","company_name":"ADC Therapeutics SA","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Zynlonta works by binding to a specific target on cancer cells, marking them for destruction."},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"tisagenlecleucel","indication_name":"diffuse large B-cell lymphoma (DLBCL) not otherwise specified","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05366257","title":"Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)","phase":"","overall_status":"COMPLETED","enrollment_count":160602,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06091865","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":904,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07181785","title":"Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.","phase":"","overall_status":"COMPLETED","enrollment_count":555,"lead_sponsor_name":"Andrés José Maria Ferreri","has_results":false},{"nct_id":"NCT05934084","title":"Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors","phase":"NA","overall_status":"RECRUITING","enrollment_count":552,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT06652152","title":"Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03391466","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":359,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT00001337","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT05349201","title":"CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)","phase":"","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04792489","title":"DALY II USA/ MB-CART2019.1 for DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":248,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT07310186","title":"Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06656234","title":"The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07493109","title":"Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Ou Bai, MD/PHD","has_results":false},{"nct_id":"NCT03936153","title":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Xynomic Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07189065","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Guangzhou Lupeng Pharmaceutical Company LTD.","has_results":false},{"nct_id":"NCT05234684","title":"A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT07393204","title":"Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Andrés José Maria Ferreri","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT04824794","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":130,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT07398638","title":"Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02445248","title":"Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06748521","title":"Dynamic CtDNA-guided Targeted Therapy in DLBCL","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":108,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06793410","title":"Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT07124936","title":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":97,"lead_sponsor_name":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04772989","title":"A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT03547115","title":"A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":84,"lead_sponsor_name":"MEI Pharma, Inc.","has_results":false},{"nct_id":"NCT07084662","title":"Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05563844","title":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT07035379","title":"A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Zhejiang Teruisi Pharmaceutical Inc.","has_results":false},{"nct_id":"NCT02580552","title":"Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"miRagen Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03992339","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Antengene Corporation","has_results":true},{"nct_id":"NCT07494565","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02875548","title":"A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT07397832","title":"CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03287817","title":"Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Autolus Limited","has_results":true},{"nct_id":"NCT06464861","title":"Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07493148","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Ou Bai, MD/PHD","has_results":false},{"nct_id":"NCT07371923","title":"Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT07078500","title":"Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07523737","title":"Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT05364424","title":"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04537715","title":"Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT06867536","title":"Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Liling Zhang","has_results":false},{"nct_id":"NCT06682130","title":"Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07502118","title":"NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Health Institutes of Turkey","has_results":false},{"nct_id":"NCT07480850","title":"Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06647940","title":"Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"Sun Yat-sen University","has_results":false}],"total":50},"guidelines":[{"drug_id":"rituximab","guideline_body":"FDA label","recommendation":"RITUXAN HYCELA is indicated for previously untreated diffuse large B-cell lymphoma in combination with CHOP or other anthracycline-based chemotherapy regimens.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"rituximab","guideline_body":"FDA label","recommendation":"RITUXAN HYCELA is indicated for previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC).","line_of_therapy":"1L|2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}